Non Hodgkin Lymphoma Clinical Trial

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Summary

RATIONALE: Diagnostic procedures, such as anal swab collection, digital rectal examination, and anal endoscopy and biopsy, may help find and diagnose anal and genital human papillomavirus infection and squamous intraepithelial lesions and help doctors plan better treatment.

PURPOSE: This clinical trial is studying ways to detect anal and genital human papillomavirus infection and squamous intraepithelial lesions in HIV-positive patients enrolled in an AIDS cancer clinical trial.

View Full Description

Full Description

OBJECTIVES:

Primary

To determine if various pharmacotherapeutic agents investigated in primary AIDS Malignancy Clinical Trials (AMC) for diseases other than human papillomavirus (HPV)-associated neoplasia have any preliminary evidence of activity against anogenital HPV infection or anogenital squamous intraepithelial lesions (ASIL) in HIV-positive patients participating in these trials.
To describe changes in the types of anal HPV present and the prevalence of ASIL in patients treated on these studies.
To evaluate cervical HPV infection and cervical/vulvovaginal disease in HIV-positive women participating in these trials.
To describe changes in cervical HPV infection and cervical/vulvovaginal disease in these women after undergoing various study treatments.

OUTLINE: This is a multicenter study.

Patients undergo anal swab collection at baseline to obtain samples for anal cytology, anal human papillomavirus (HPV) typing, and other HPV-related testing (e.g., HPV viral load). Digital rectal examinations (DRE) are also performed as part of the baseline physical examination. Female patients also undergo cervical swab collection for cervical HPV testing and cytology, as well as colposcopy (if available) of the cervix and vulvovaginal region to completely assess lower genital tract HPV-related lesions. At sites where high-resolution anoscopy (HRA) is available, patients are encouraged, but not required, to have an HRA with biopsy of any visualized lesions within 30 days of collection of the swabs.

After baseline assessments, patients undergo treatment with the investigative agent according to the study protocol requirements. If study treatment continues beyond 6 months, additional anal and cervical swabs are obtained for anal and cervical HPV and cytology along with DREs every 6 months until completion of study treatment and at the final study visit. Patients may also undergo additional HRA with biopsy and/or colposcopy of the lower genital tract with biopsy (women only) at this time. Patients with an abnormal anal cytology or histology are referred for HRA per local standard of care. If HRA is not available at the treatment site, patients undergo a DRE, and those with an abnormal DRE are referred for evaluation by a surgeon.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Serologic documentation of HIV infection by any FDA-approved tests

Enrolled in an AIDS Malignancy Clinical Trials Consortium (AMC) clinical trial of any new or existing pharmacotherapeutic agent for treatment of disease other than human papillomavirus (HPV)-associated neoplasia

AMC study must have an accrual target of > 15 patients

PATIENT CHARACTERISTICS:

ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
Life expectancy ≥ 3 months
Not pregnant or nursing

Patients receiving myelosuppressive therapy must meet the following criteria:

ANC > 1,000/μL
Platelet count > 50,000/μL
Evaluated before treatment or completely recovered from their nadir
Able to understand and willing to sign a written informed consent document
No bleeding disorder or requirement for anticoagulation that would contraindicate any biopsy of the anal canal

PRIOR CONCURRENT THERAPY:

See Disease Characteristics

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

47

Study ID:

NCT00695422

Recruitment Status:

Completed

Sponsor:

AIDS Malignancy Consortium

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Rebecca and John Moores UCSD Cancer Center
La Jolla California, 92093, United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles California, 90089, United States
UCLA Clinical AIDS Research and Education (CARE) Center
Los Angeles California, 90095, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco California, 94115, United States
Cancer Research Center of Hawaii
Honolulu Hawaii, 96813, United States
Boston University Cancer Research Center
Boston Massachusetts, 02118, United States
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States
Baylor University Medical Center - Houston
Houston Texas, 77030, United States
Benaroya Research Institute at Virginia Mason Medical Center
Seattle Washington, 98101, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

47

Study ID:

NCT00695422

Recruitment Status:

Completed

Sponsor:


AIDS Malignancy Consortium

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider